Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: zileuton

« Back to Dashboard

Summary for Generic Name: zileuton

Tradenames:2
Patents:1
Applicants:1
NDAs:2
Drug Master File Entries: see list6
Suppliers: see list2
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: zileuton

Clinical Trials for: zileuton

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Status: Recruiting Condition: Chronic Myelogenous Leukemia

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Status: Terminated Condition: Chronic Myelogenous Leukemia

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Status: Completed Condition: Sickle Cell Disease

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
Status: Terminated Condition: Asthma

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients
Status: Completed Condition: Asthma

Zileuton and Exhaled Nitric Oxide in Asthmatics
Status: Completed Condition: Asthma

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Status: Terminated Condition: Pulmonary Disease, Chronic Obstructive

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis
Status: Completed Condition: Idiopathic Pulmonary Fibrosis

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging
Status: Completed Condition: Lung Inflammation

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
Status: Completed Condition: Tobacco Use Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc
ZYFLO
zileuton
TABLET;ORAL020471Dec 9, 1996DISCNNo<disabled><disabled>
Chiesi Usa Inc
ZYFLO CR
zileuton
TABLET, EXTENDED RELEASE;ORAL022052May 30, 2007RXYes6,183,778<disabled>Y<disabled>
Chiesi Usa Inc
ZYFLO
zileuton
TABLET;ORAL020471Dec 9, 1996RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc